Is there an effect of local vaginal estrogen treatment on the hemostatic parameters in postmenopausal women?

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519539-41-00

Enrollment

Registered

2025-03-26

Start date

2025-05-13

Completion date

Unknown

Last updated

2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment for vaginal atrophy

Brief summary

Compare changes in thrombin generation and fibrinolysis in postmenopausal women with and without VTE using vaginal estrogen in three months

Detailed description

Compare changes in contact activation system in women receiving vaginal estrogen in three months

Interventions

DRUGESTRADIOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Compare changes in thrombin generation and fibrinolysis in postmenopausal women with and without VTE using vaginal estrogen in three months	—

Secondary

Measure	Time frame
Compare changes in contact activation system in women receiving vaginal estrogen in three months	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026